1Y Close · As of Aug 26, 2026
PCL manufactures pharmaceuticals. Pharmaceuticals
Legal name: PCL. Inc
In fiscal year 2024, PCL (241820) reported revenue of 1.2 billion KRW, down 85.2% from 8.4 billion KRW a year earlier.
Operating profit was -27.1 billion KRW and net income was -52.8 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 16.8 billion KRW.
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2024 | 1.2B | -27.1B | -52.8B |
| 2023 | 8.4B | -16.1B | -20.3B |
| 2022 | 37.2B | -8.2B | -4.0B |
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is 4.2x the delisting threshold.
Administrative Designation: Unable to determine due to missing data.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | 기타시장안내 (정기보고서 미제출 관련 상장폐지 절차 미진행) |